Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI Radiomics Evaluation of Toripalimab + Albumin-bound Paclitaxel + Nedaplatin as Neoadjuvant Therapy for Esophageal Cancer
ChiCTR2500106521Phase 4Not yet recruiting
- Sponsor
- Gansu Provincial People's Hospital
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Gansu Provincial People's Hospital. Primary endpoint: Radiomics-based AI model to predict pathological complete response (pCR) after neoadjuvant therapy. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500106521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106521.